Stable episodic memory and higher education do not influence the rate of Alzheimer's disease pathology as measured by plasma p‐tau217
Alzheimer's & Dementia · 2026-11 · 22 (11)
DOI: 10.1002/alz.71920 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia, online erschienen am 04.11.2026. Verfasst von Bárbara Avelar-Pereira und 9 weiteren Autor:innen. Beteiligte Einrichtung: Aging Research Center, Karolinska Institutet and Stockholm University, Stockholm, Sweden. Hauptthemen laut MEDLINE: Alzheimer Disease, tau Proteins, Memory, Episodic, Educational Status. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Rönström Family Foundation, Regionalt Forskningsstöd, Michael J. Fox Foundation.
Themen: Demenz
Abstract (Originalsprache)
INTRODUCTION Blood‐based biomarkers, particularly phosphorylated tau 217 (p‐tau217), can detect early Alzheimer's disease (AD) neuropathological changes. Recent work has shown that p‐tau217 is lower in individuals with stable cognition and higher education. These factors may protect against AD pathology. METHODS We evaluated whether individuals with stable episodic memory and higher education exhibited lower levels of or slower increases in p‐tau217 using longitudinal data from the population‐based Betula study ( n = 1005; 1531 samples). RESULTS P‐tau217 increased with age over 10 years ( p < 0.001), with the steepest increase seen in individuals with accelerated episodic‐memory decline ( p < 0.001). There were no differences in p‐tau217 trajectories between individuals with lower or higher education ( p = 0.386) or with well‐maintained or age‐typical decline in episodic memory ( p = 0.885). The null finding for education was replicated in the BioFINDER‐2 cohort ( p = 0.14). DISCUSSION Plasma p‐tau217 can detect early pathological changes in population‐based settings, but our findings do not support the notion that higher education or well‐maintained memory protects against AD neuropathological changes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Aging Research Center, Karolinska Institutet and Stockholm University, Stockholm, Sweden.
- Department of Psychiatry and Behavioral Sciences, School of Medicine, Stanford University, Stanford, California, USA.
- Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Lund, Sweden.
- Department of Clinical Sciences, Psychiatry, Umeå University, Umeå, Sweden.
- Memory Clinic, Skåne University Hospital, Malmö, Sweden.
- Wallenberg Center for Molecular Medicine, Lund University, Lund, Sweden.
Förderung
- Rönström Family Foundation
- Regionalt Forskningsstöd
- Michael J. Fox Foundation
- Swedish Brain Foundation
- Ingvar Kamprad Foundation
- Lilly Research Award Program
- Swedish Alzheimer Foundation
- ERA PerMed
Zitieren
APA
Avelar-Pereira, B., Spotorno, N., Dolado, A. O., Bali, D., Adolfsson, A. N., Mattsson-Carlgren, N., Palmqvist, S., Janelidze, S., Hansson, O., & Nyberg, L. (2026). Stable episodic memory and higher education do not influence the rate of Alzheimer's disease pathology as measured by plasma p‐tau217. Alzheimer's & Dementia, 22(11). https://doi.org/10.1002/alz.71920
Vancouver
Avelar-Pereira B, Spotorno N, Dolado AO, Bali D, Adolfsson AN, Mattsson-Carlgren N, et al. Stable episodic memory and higher education do not influence the rate of Alzheimer's disease pathology as measured by plasma p‐tau217. Alzheimer's & Dementia. 2026;22(11). doi:10.1002/alz.71920
BibTeX
@article{AvelarPereira2026,
author = {Avelar-Pereira, Bárbara and Spotorno, Nicola and Dolado, Anna Orduña and Bali, Divya and Adolfsson, Annelie Nordin and Mattsson-Carlgren, Niklas and Palmqvist, Sebastian and Janelidze, Shorena and Hansson, Oskar and Nyberg, Lars},
title = {Stable episodic memory and higher education do not influence the rate of Alzheimer's disease pathology as measured by plasma p‐tau217},
journal = {Alzheimer's & Dementia},
year = {2026},
volume = {22},
number = {11},
doi = {10.1002/alz.71920}
}
EUVIMED